These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
637 related articles for article (PubMed ID: 27449797)
21. Altered γ-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressants. Pehrson AL; Sanchez C Drug Des Devel Ther; 2015; 9():603-24. PubMed ID: 25653499 [TBL] [Abstract][Full Text] [Related]
22. Ketamine for Treatment-Resistant Depression: a New Advocate. Pérez-Esparza R Rev Invest Clin; 2018; 70(2):65-7. PubMed ID: 29718013 [TBL] [Abstract][Full Text] [Related]
23. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038 [TBL] [Abstract][Full Text] [Related]
24. Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Krystal JH; Sanacora G; Duman RS Biol Psychiatry; 2013 Jun; 73(12):1133-41. PubMed ID: 23726151 [TBL] [Abstract][Full Text] [Related]
25. Neuroimaging-Derived Biomarkers of the Antidepressant Effects of Ketamine. Zavaliangos-Petropulu A; Al-Sharif NB; Taraku B; Leaver AM; Sahib AK; Espinoza RT; Narr KL Biol Psychiatry Cogn Neurosci Neuroimaging; 2023 Apr; 8(4):361-386. PubMed ID: 36775711 [TBL] [Abstract][Full Text] [Related]
26. Two cellular hypotheses explaining the initiation of ketamine's antidepressant actions: Direct inhibition and disinhibition. Miller OH; Moran JT; Hall BJ Neuropharmacology; 2016 Jan; 100():17-26. PubMed ID: 26211972 [TBL] [Abstract][Full Text] [Related]
27. The glutamatergic system and its relation to the clinical effect of therapeutic-sleep deprivation in depression - an MR spectroscopy study. Murck H; Schubert MI; Schmid D; Schüssler P; Steiger A; Auer DP J Psychiatr Res; 2009 Jan; 43(3):175-80. PubMed ID: 18533184 [TBL] [Abstract][Full Text] [Related]
28. The promise of ketamine for treatment-resistant depression: current evidence and future directions. DeWilde KE; Levitch CF; Murrough JW; Mathew SJ; Iosifescu DV Ann N Y Acad Sci; 2015 May; 1345(1):47-58. PubMed ID: 25649308 [TBL] [Abstract][Full Text] [Related]
29. Therapeutic Mechanisms of Ketamine. Mihaljević S; Pavlović M; Reiner K; Ćaćić M Psychiatr Danub; 2020; 32(3-4):325-333. PubMed ID: 33370729 [TBL] [Abstract][Full Text] [Related]
32. Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder. Rong C; Park C; Rosenblat JD; Subramaniapillai M; Zuckerman H; Fus D; Lee YL; Pan Z; Brietzke E; Mansur RB; Cha DS; Lui LMW; McIntyre RS Int J Environ Res Public Health; 2018 Apr; 15(4):. PubMed ID: 29673146 [TBL] [Abstract][Full Text] [Related]
33. Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion. Pennybaker SJ; Niciu MJ; Luckenbaugh DA; Zarate CA J Affect Disord; 2017 Jan; 208():560-566. PubMed ID: 27839782 [TBL] [Abstract][Full Text] [Related]
34. Neurophysiological evidence that frontoparietal connectivity and GABA-A receptor changes underpin the antidepressant response to ketamine. Sumner RL; McMillan RL; Forsyth A; Muthukumaraswamy SD; Shaw AD Transl Psychiatry; 2024 Feb; 14(1):116. PubMed ID: 38402231 [TBL] [Abstract][Full Text] [Related]
35. The role of glutamate on the action of antidepressants. Hashimoto K Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1558-68. PubMed ID: 20600468 [TBL] [Abstract][Full Text] [Related]
36. New Treatment Strategies of Depression: Based on Mechanisms Related to Neuroplasticity. Huang YJ; Lane HY; Lin CH Neural Plast; 2017; 2017():4605971. PubMed ID: 28491480 [TBL] [Abstract][Full Text] [Related]
37. Ketamine reverses stress-induced depression-like behavior and increased GABA levels in the anterior cingulate: an 11.7 T 1H-MRS study in rats. Perrine SA; Ghoddoussi F; Michaels MS; Sheikh IS; McKelvey G; Galloway MP Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jun; 51():9-15. PubMed ID: 24246571 [TBL] [Abstract][Full Text] [Related]
38. Neurophysiological Changes Associated with Antidepressant Response to Ketamine Not Observed in a Negative Trial of Scopolamine in Major Depressive Disorder. Park L; Furey M; Nugent AC; Farmer C; Ellis J; Szczepanik J; Lener MS; Zarate CA Int J Neuropsychopharmacol; 2019 Jan; 22(1):10-18. PubMed ID: 30184133 [TBL] [Abstract][Full Text] [Related]
39. Motor-Activity Markers of Circadian Timekeeping Are Related to Ketamine's Rapid Antidepressant Properties. Duncan WC; Slonena E; Hejazi NS; Brutsche N; Yu KC; Park L; Ballard ED; Zarate CA Biol Psychiatry; 2017 Sep; 82(5):361-369. PubMed ID: 28457485 [TBL] [Abstract][Full Text] [Related]
40. A hypothesis of monoamine (5-HT) - Glutamate/GABA long neural circuit: Aiming for fast-onset antidepressant discovery. Li YF Pharmacol Ther; 2020 Apr; 208():107494. PubMed ID: 31991195 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]